New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
09:24 EDTPRGO, TEVAPerrigo announces settlement in Proair HFA patent case
Perrigo (PRGO) and its partner, Catalent, announced that they have settled their first to file Hatch Waxman litigation with Teva (TEVA) with respect to a generic version of Proair HFA. Pursuant to the settlement, Perrigo has a limited quantity license to launch a generic version of Proair HFA starting on December 19, 2016 and an unlimited quantity license beginning after June 30, 2018. Proair® HFA indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. Brand sales were approximately $1.4B over the last 52-weeks according to Symphony Health Solutions.
News For PRGO;TEVA From The Last 14 Days
Check below for free stories on PRGO;TEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
07:04 EDTTEVATeva raises FY14 EPS view to $4.90-$5.10 in exclusive Copaxone scenario
Subscribe for More Information
07:03 EDTTEVATeva reports Q2 EPS $1.23, consensus $1.22
Subscribe for More Information
July 30, 2014
08:15 EDTPRGOPerrigo files patent challenge for generic version of Taro's Topicort
Subscribe for More Information
July 25, 2014
07:14 EDTTEVATeva August weekly volatility elevated into Q2 and outlook
Teva August weekly call option implied volatility is at 34, August is at 25, September and January is at 22; compared to its 26-week average of 27 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on July 31.
July 24, 2014
12:56 EDTPRGOPerrigo confirms AB therapeutic equivalent rating for testosterone gel 1.0%
Subscribe for More Information
07:27 EDTTEVASome of Teva's biggest investors to vote against re-electing directors, WSJ says
Subscribe for More Information
06:45 EDTTEVATeva price target raised to $70 from $65 at Barclays
Subscribe for More Information
July 23, 2014
10:02 EDTPRGO, TEVAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTTEVA, PRGODeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTPRGOPerrigo initiated with a Buy at Deutsche Bank
Target $189.
16:08 EDTTEVATeva initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
08:11 EDTTEVAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
08:01 EDTTEVATeva completes acquisition of Labrys
Subscribe for More Information
July 18, 2014
09:35 EDTPRGOPerrigo would rather make acquisitions than be sold, dealReporter says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use